PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Abstract 7441: Mapping immune clonotypes in prostate cancer using spatial V(D)J to resolve cancer vaccine response

View Full Paper
EHEirik HøyeKSKarishma SajnaniRNReetta Nätkin

Key Points

  • This study aims to understand the spatial distribution and function of immune clones in the prostate tumor microenvironment and their relationship to vaccine responses.
  • Applied spatial V(D)J sequencing to map T and B cell clonotypes in prostate tissue.
  • Combined long- and short-read analysis of the CDR3 region.
  • Used prior data from a phase 1/2a clinical trial of the UV1 vaccine with radiation therapy.
  • Investigated changes in the TME and T cell repertoires pre- and post-vaccination.
  • Identified distinct T cell receptor motif signatures in pre-vaccination tissue of responders versus non-responders.
  • Observed differences in transcriptomic profiles linked to immune response timing.
  • Demonstrated spatial V(D)J analysis as a tool for exploring immune-tumor interactions.

Abstract

Abstract Purpose: The prostate tumor microenvironment (TME) is immunologically “cold,” limiting the efficacy of immunotherapy. Vaccine-induced immune activation has shown promise, but the spatial distribution and function of immune clones within the TME remain poorly understood. Methods: We applied spatial V(D)J sequencing, combining long- and short-read analysis of the CDR3 region, to map T and B cell clonotypes alongside gene expression signatures directly in prostate tissue while preserving spatial context. Prior data from a phase 1/2a clinical trial (NCT01784913) of the telomerase (hTERT) peptide vaccine UV1, administered in combination with radiation therapy, used TCRseq to investigate changes in the TME and T cell repertoires before and after vaccination, as well as factors distinguishing the cancer vaccine non-responders from the responders who had a very favourable outcome. Results: TCRseq data revealed distinct profiles in tissue prior to vaccination that differentiated responders from non-responders. Notably, a T cell receptor motif signature in pre-vaccination tissue was associated with patients who mounted an early immune response to the vaccine. Differences in transcriptomic profiles and T cell repertoires were observed among patients with early, late, or no immune response, linking immune contexture to clinical outcomes. Conclusions: Our findings provide high-resolution insights into immune-tumor interactions in prostate cancer, demonstrating that specific immune clonotypes underlie effective vaccine responses and may inform future immunotherapy strategies, and that spatial V(D)J analysis can be leveraged to explore the spatial contexture of the prostate cancer tumor microenvironment. Citation Format: Eirik Høye, Karishma Sajnani, Reetta Nätkin, Sini Hakkola, Antti Kiviaho, Thomas Cecchetto, Anthony Mathelier, Matti Nykter, Wolfgang Lilleby, Sini Eerola, Alfonso Urbanucci, Tapio Visakorpi, Heini Kallio. Mapping immune clonotypes in prostate cancer using spatial V(D)J to resolve cancer vaccine response abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7441.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Høye et al. (2026) studied this question.

synapsesocial.com/papers/69d1fc70a79560c99a0a1faehttps://doi.org/10.1158/1538-7445.am2026-7441
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract PR001: Immune spatial organization predicts metastasis risk in aggressive localized prostate cancer2026
  2. 2Abstract 7044: Transcriptome and TCR repertoire in human telomerase reverse transcriptase peptide vaccine treated metastatic prostate cancer patients2024
  3. 3Abstract PR021: A cancer vaccine for de novo metastatic prostate cancer: learning patients stratification from the UV1 trial2026
  4. 4Abstract PR010: High-dimensional spatial profiling identifies distinct and targetable tumor-infiltrating lymphocyte phenotypes in localized prostate cancer2026
  5. 5Abstract 6210: Spatial compartmentalization of tumor and immune cellular architecture defines opposing prognostic roles in prostate cancer2026